Jump to content

KEYNOTE-B99 Clinical Trial


Recommended Posts

Visit https://merckoncologyclinicaltrials.com/en-us/patient/trial/NCT04924101 or call 888-577-8839 for more information

KEYNOTE-B99 Efficacy and safety of Pembrolizumab plus investigational agents in combination with chemotherapy as first-line treatment in extensive-stage small cell lung cancer (ES-SCLC) (NCT04924101)

You may be able to join this study if you have ES-SCLC and have not yet received treatment for your SCLC.

The trial drugs you get will depend on which group you are placed in. This trial has 3 groups:

Group 1: Will get pembro, MK-4830, and chemo

Group 2: Will get pembro, MK-5890, and chemo

Group 3: Will get pembro, lenvatinib, and chemo

Your chance of being in each group depends on what groups are open for enrollment at the time you start the trial. The trial doctor or trial staff can tell you which groups are open. You, your trial doctor, and the trial staff will know what you are getting.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.